Yes
o
|
No
x
|
Yes
o
|
No
x
|
Yes
o
|
No
x
|
This
Report of Foreign Issuer on Form 6-K is incorporated by reference
into the
Post-Effective Amendments on Forms F-3 and S-8 to Form F-4 Registration
Statement of Elan Corporation, plc (Registration No. 333-12756),
the
Registration Statement on Form F-3 of Elan Corporation, plc and
Athena
Neuroscience Finance, LLC (Registration No. 333-13130), and the
Registration Statements on Form S-8 of Elan Corporation, plc (Registration
Nos. 333-13996, 333-12344, 333-11940, 333-09644, 333-09284, 333-09048,
333-08384, 333-07361, 333-07136, 333-14240, 33-27506, 333-100252
and
333-121021).
|
Exhibit
|
Description
|
99.1
|
Press
release dated October 15, 2007 titled:
Elan
and Biogen Idec announce that FDA will extend regulatory review
period for
TYSABRI® for Crohn’s disease.
|
Press
release dated October 15, 2007 titled:
Elan
Update.
|
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant
has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
|
||
ELAN
CORPORATION, plc
By: /s/
William F.
Daniel
William
F. Daniel
EVP,
Company Secretary
|